Table 1.

comparison between the DMARD-used group and only GC group in all the GCA completed the 12 months follow up

Patients’ characteristicsGCA with completed follow-up (n=73)
GCA treated with DMARD=36GCA not treated with DMARD=37
Age, median (range) years73.5 (60-89)76 (60-89)
Sex, Females, n (%)23 (64)24 (65)
US halo score (HS)/IMT median (range)
Temporal artery HS11 (0-23)13 (1-22)
Axillary artery HS12 (0-21)12 (0-18)
Axillary artery IMT (mm)0.77 (0.33-2.6)0.82 (0.39-1.21)
Total HS22.5 (2-41)21 (5-40)
Clinical features, n (%)
Temporal headache25(69)30 (81)
Scalp tenderness17 (47)19 (51)
Jaw & Tongue claudication22 (61)24 (65)
Polymyalgic symptoms21 (58)13 (35)
Constitutional symptoms21 (58)18 (49)
Any visual disturbance15 (42)21 (57)
Partial or complete vision loss8 (22)7 (19)
History of PMR6 (17)3 (8)
Exam findings, n (%)
Temporal artery abnormality24 (67)30 (81)
AION/ CRAO8 (22)6 (16)
Ocular nerve palsy1 (3)3 (8)
Lab markers at baseline, median (range)
CRP mg/dL,72.2 (6.4-292)59 (6-206)
ESR mm/hr67 (9-130)57 (2-120)
GC treatment, median (range)
GC starting dose, (baseline)45 (0-60)50 (0-60)
GC dose at 12m,5 (0-25)2.5 (0-10)
Cumulative GC dose at 12m4627.5 (2600-10260.5)4622.5 (944-10737.5)
Remission with prednisolone dose ≤5 mg at 12m, n (%)32 (89)33 (89)